Diabetes Drug Market: By Drugs (Oral Drugs {Biguanides, Sulfonylureas, Meglitinides and D-Phenylalanine Derivatives, Thiazolidinediones, DPP-4 Inhibitors, Alpha-glucosidase Inhibitors, Bile Acid Sequestrants, Others}, Injectable Drugs{Insulin, Exenatide, Liragultide, Pramlintide}) and By Type of Diabetes(Type 1 Diabetes, Type 2 Diabetes) - Forecast 2027

ID: VPR/HC/1269 Publishing Year: November 2021 Pages: 130 Format:   


Diabetes Drug Market Overview:

The global Diabetes Drug Market was valued at $ 54.21 billion in 2020 and is expected to reach $ 82.34 billion by 2027, registering a CAGR of 6.15% from 2021 to 2027.

Diabetes is a condition characterized by an excessively high insulin level in the blood. Diabetes drugs work by decreasing blood glucose levels, which is how they treat diabetes mellitus. Type 1 Diabetes is caused by a shortage of insulin, while Type 2 Diabetes is caused by cells that become resistant to insulin. The approval of new medicines for the treatment of diabetes, such as Canagliflozin and Dapagliflozin, would open up many possibilities for new and current companies in the global diabetes pharmaceuticals industry.

Because of low-cost insulin therapy and the most efficient diabetes treatment, particularly for type 2 diabetes, the insulin sector dominates the worldwide Diabetes Drug Market. As a result, the fast-growing insulin sector is expected to drive the global Diabetes Drug Market during the projected period. This has also persuaded commercial and public sector investors to engage in research and development, resulting in faster market expansion.

The Diabetes Drug Market's substantial rise may be due to factors such as the rising incidence of diabetes and the growing number of health awareness initiatives launched by different health organizations. Currently, Type-1 diabetes accounts for approximately 10% of all diabetes cases, with Type-2 accounting for the remainder.

North America had the largest share of the Diabetes Drug Market in 2020, followed by Asia-Pacific. Increased obesity among individuals as a result of poor diets and sedentary lifestyles is mainly to blame for the rise in diabetes patients. The Diabetes Drug Market in Asia-Pacific is primarily driven by China and India's rising demand for diabetic medicines. China now has about 120 million diabetic patients, while India's diabetes population is projected to grow to 92 million by 2027.

Key Players

  • Abbott
  • Amgen
  • AstraZeneca
  • Boehringer Ingelheim
  • Eli Lilly and Company
  • Merck & Co.
  • Novo Nordisk
  • Sanofi

Segmental Analysis

By Drugs

Oral Drugs

  • Biguanides
  • Sulfonylureas
  • Meglitinides and D-Phenylalanine Derivatives
  • Thiazolidinediones
  • DPP-4 Inhibitors
  • Alpha-glucosidase Inhibitors
  • Bile Acid Sequestrants
  • Others (Combination Pills)

Injectable Drugs

  • Insulin
  • Exenatide
  • Liragultide
  • Pramlintide

By Type of Diabetes

  • Type 1 Diabetes
  • Type 2 Diabetes

By Geography

  • North America
  • Europe
  • Asia Pacific
  • LAMEA

Regional Analysis:

In 2019-20, North America generated huge revenue, which is projected to grow at a CAGR of more than 6% during the projection year. This is mainly due to an increase in diabetes cases in North America, which is caused by stress, poor diets, and obesity. Diabetes affects more than 30 million people in North America, with that figure projected to rise to 34 million by 2025. In 2019, the United States alone had over 25 million diabetic sufferers. The market for diabetes drugs in North America is dominated by the United States. In addition to favorable government reimbursement policies and sophisticated healthcare infrastructure, the diabetic medication market in this area is growing. Southeast Asian countries are anticipated to have increased demand in the future years, owing to local government and healthcare organizations' efforts to raise knowledge about diabetes, medicines, and devices. Over the last decade, the diabetes population in this area has risen at an alarming pace. The absence of healthcare infrastructure and coordinated supply chains in Asia-Pacific developing countries is a significant issue for the diabetic medicines industry, resulting in pricing differences.

Due to the existence of a large patient population, constantly expanding economies, and rising demand for improved treatment, Asia Pacific is the fastest expanding area for the industry.

The Middle East and Africa, on the other hand, have the smallest proportion of the worldwide Diabetes Drugs Market owing to weak economic conditions, particularly in Africa. The Middle East and Africa market is dominated by the Middle East and Africa due to the well-developed healthcare industry and high healthcare spending.



Frequently Asked Questions
Diabetes Drug Market is predicted to grow at 6.15% through forecast period of 2020-2027
By 2027, worth USD 82.34 Billion is estimated for the global market.
Because of low-cost insulin therapy and most efficient diabetes treatment, particularly for type 2 diabetes, the insulin sector dominates the worldwide Diabetes Drug Market. As a result, the fast-growing insulin sector is expected to drive the global Diabetes Drug Market during the projected period.
Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Merck & Co., Novo Nordisk and Sanofi

Type Here for table of content.


PURCHASE OPTIONS




    ADD TO CART

CONTACT US
CALL US ON
( +91-935-919-4956 )

CONTACT EMAIL
[email protected]
PURCHASE OPTIONS




    ADD TO CART

CONTACT US
CALL US ON
( +91-935-919-4956 )

CONTACT EMAIL
[email protected]